EcoDrugPlus

Ribosomal Protein S9

Ensembl ID : ENSCHAG00000013264
Gene Symbol: RPS9
3 Cross references
237 Possible Orthologues:

Ribosomal Protein Sa

Ensembl ID : ENSCHAG00000023209
Gene Symbol: RPSA
3 Cross references
518 Possible Orthologues:

Ribosomal Protein Lateral Stalk Subunit P0

Ensembl ID : ENSCHAG00000007441
Gene Symbol: RPLP0
3 Cross references
403 Possible Orthologues:

Ribosomal Protein, Large, P1

Ensembl ID : ENSCHAG00000025085
Gene Symbol: RPLP1
1 Cross references
384 Possible Orthologues:

Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSCHAG00000009469
Gene Symbol: SERPINC1
1 Cross references
202 Possible Orthologues:

Si:dkey-91m11.5

Ensembl ID : ENSCHAG00000020003
Gene Symbol: SI:DKEY-91M11.5
1 Cross references
203 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSCHAG00000006779
Gene Symbol: SCN5LAB
1 Cross references
263 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Viii, Alpha Subunit A

Ensembl ID : ENSCHAG00000017341
Gene Symbol: SCN8AA
1 Cross references
263 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Viii, Alpha Subunit B

Ensembl ID : ENSCHAG00000005584
Gene Symbol: SCN8AB
1 Cross references
263 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSCHAG00000007432
Gene Symbol: SCN12AA
1 Cross references
245 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSCHAG00000017312
Gene Symbol: SCN4A
1 Cross references
188 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSCHAG00000017782
Gene Symbol: LOC105904729
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).